|
Index | - | P/E | - | EPS (ttm) | -7.65 | Insider Own | 16.37% | Shs Outstand | 473.06M | Perf Week | -12.94% |
Market Cap | 2.38B | Forward P/E | - | EPS next Y | -0.83 | Insider Trans | 0.00% | Shs Float | 407.89M | Perf Month | 1.63% |
Income | - | PEG | - | EPS next Q | -0.21 | Inst Own | 60.50% | Short Float | 4.52% | Perf Quarter | 21.17% |
Sales | - | P/S | - | EPS this Y | 58.40% | Inst Trans | 1.36% | Short Ratio | 7.69 | Perf Half Y | 52.76% |
Book/sh | 3.12 | P/B | 1.60 | EPS next Y | -43.10% | ROA | - | Target Price | 6.80 | Perf Year | -49.70% |
Cash/sh | 3.26 | P/C | 1.53 | EPS next 5Y | - | ROE | - | 52W Range | 2.63 - 9.99 | Perf YTD | -26.98% |
Dividend | - | P/FCF | - | EPS past 5Y | - | ROI | - | 52W High | -50.15% | Beta | - |
Dividend % | - | Quick Ratio | 28.70 | Sales past 5Y | - | Gross Margin | - | 52W Low | 89.35% | ATR | 0.46 |
Employees | 242 | Current Ratio | 28.70 | Sales Q/Q | - | Oper. Margin | - | RSI (14) | 47.60 | Volatility | 11.08% 8.86% |
Optionable | Yes | Debt/Eq | 0.00 | EPS Q/Q | 52.10% | Profit Margin | - | Rel Volume | 0.49 | Prev Close | 4.82 |
Shortable | Yes | LT Debt/Eq | 0.00 | Earnings | Aug 11 BMO | Payout | - | Avg Volume | 2.40M | Price | 4.98 |
Recom | 1.70 | SMA20 | -4.10% | SMA50 | 1.31% | SMA200 | -11.70% | Volume | 1,191,880 | Change | 3.32% |
![]() |
|
![]() | ||||||||||||||||||||||||||||||||||||||||||
![]() | ||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||
![]() | ||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||
![]() | ||||||||||||||||||||||||||||||||||||||||||
EQRx, Inc., a pharmaceutical company, engages in developing medicines primarily for the treatment of oncology and immune-inflammatory diseases in the United States. The company's pre-registrational programs in Phase III clinical trial include Aumolertinib, an epidermal growth factor receptor (EGFR) inhibitor for the treatment of patients with EGFR-mutated non-small cell lung cancer (NSCLC); and Sugemalimab, an anti-programmed death-ligand 1 antibody for the treatment of Stage III and Stage IV NSCLC. Its other programs in pipeline include clinical and pre-clinical stage assets, which comprise Lerociclib, a small molecule cyclin-dependent kinase 4/6 inhibitor, which is in Phase II clinical trials in patients with metastatic breast cancer; EQ176, an anti-programmed death-1 antibody that is in Phase III trials for the treatment of patients with primary liver cancer; and EQ121, a selective janus kinase-1 inhibitor that is in various Phase I trials. The company was incorporated in 2019 and is headquartered in Cambridge, Massachusetts. | ||||||||||||||||||||||||||||||||||||||||||
![]() | ||||||||||||||||||||||||||||||||||||||||||
![]() |
open in yahoo | open in reuters | open in marketwatch | open in google |
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features. Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite